Condensed Consolidated Statements of Operations - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Operating expenses:
Research and development	[1]	$ 53,813	$ 24,170	$ 105,154	$ 41,878
General and administrative	[2]	10,310	6,141	19,052	10,323
Total operating expenses		64,123	30,311	124,206	52,201
Interest expense		1,580	0	3,197	0
Other (income) expense		(21)	(138)	268	204
Loss before income taxes		(65,682)	(30,173)	(127,671)	(52,405)
Income tax expense (benefit)		88	(265)	233	820
Net loss		$ (65,770)	$ (29,908)	$ (127,904)	$ (53,225)
Net loss per common share — basic and diluted (in USD per share)		$ (0.99)	$ (0.50)	$ (1.97)	$ (0.90)
Weighted average common shares outstanding — basic and diluted (in shares)		66,666,876	59,459,500	64,997,698	59,353,966
Research and development
Costs allocated from RSL, RSI, and RSG		$ 246	$ 565	$ 2,434	$ 1,103
General and administrative
Costs allocated from RSL, RSI, and RSG		$ 949	$ 694	$ 2,174	$ 1,509

[1] Includes $246 and $565 of costs allocated from RSL, RSI, and RSG during the three months ended September 30, 2018 and 2017, respectively, and $2,434 and $1,103 of costs allocated from RSL, RSI, and RSG during the six months ended September 30, 2018 and 2017, respectively. Also includes share-based compensation expense (see Note 8(D)).

[2] Includes $949 and $694 of costs allocated from RSL, RSI, and RSG during the three months ended September 30, 2018 and 2017, respectively, and $2,174 and $1,509 of costs allocated from RSL, RSI, and RSG during the six months ended September 30, 2018 and 2017, respectively. Also includes share-based compensation expense (see Note 8(D)).